Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Compugen's COM701+COM902?
COM701+COM902 is a monoclonal antibody commercialized by Compugen, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata,...